According to the American Diabetes Association, some 25.8 million children and adults in the United States, 8.3% of the population, suffer from diabetes as of a January 26, 2011 released fact sheet.
Decision Diagnostics’ GenStrip™, the affordable alternative strip for use with OneTouch® Ultra® meters, diabetics could be saving roughly 50% on their 3-8 daily blood glucose testing measures.
The speculation of DECN being bought out comes from common sense for those familiar with the M&A strategy of J&J.
Decision Diagnostics Takes Victory In Major Case Ruling
If you consider that the diabetes testing market globally is worth around $23 billion annually, expected to grow to $30 billion by 2017, and approximately 3.4 million diabetics in the U.S. who use or have used J&J’s Ultra meters, taking out the competition by buying them, since they can’t block them anymore, seems like the only solution and a major win for DECN.